Fines upheld for Advanz Pharma over thyroid drug price increases
By 
Julia Robinson2023-08-11T10:40:00
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
The UK Competition & Markets Authority’s (CMA) decision to fine Advanz Pharma for charging the National Health Service (NHS) ‘excessive and unfair’ prices for liothyronine tablets has been upheld by the Competition Appeal Tribunal.
The decision means that Advanz Pharma, together with its two former owners, private equity groups Hg Capital and Cinven, face combined fines of over £84 million.